Skip to main content
Evidence-Based Supplement Research
Evidence-Based Supplement Research
Pillser
Search
Sign UpLog In

L-Carnitine and Reduced Tumor Necrosis Factor Alpha

Research synthesisModerate evidenceSmall effect3 studies · 3 beneficial · 0 neutral · 0 harmful

Across all 3 studies, L-carnitine supplementation consistently reduced Tumor Necrosis Factor Alpha (TNF-α) with small effect sizes. One meta-analysis (n=3,255) and one randomized controlled trial (1,000 mg/day for 56 days) both reported significant reductions. The median study duration was 56 days, indicating effects are typically observed at 8 weeks.

  • Effective dose range: 1000 mg/day (2 × 500 mg/day)
  • Studied populations: obese patients, adults with impaired glucose tolerance or diabetes

Caveats: Evidence base is small (only 3 studies) — conclusions should be considered preliminary. Available evidence is overwhelmingly positive — clinical literature in this area is subject to publication bias (null-result studies are less likely to be published or indexed).

Generated Jun 12, 2026
Doses used in studies
  • mg/day: 1,000 (median 1,000, IQR 1,000–1,000) — 1 study
Time to effect
Median: 8 weeks · IQR 8 weeks–8 weeks · Range 8 weeks–8 weeks — Reported in 1 of 3 studies
3 of 3 papers
Back to top